Literature DB >> 19732782

Targeting NRF2 signaling for cancer chemoprevention.

Mi-Kyoung Kwak1, Thomas W Kensler.   

Abstract

Modulation of the metabolism and disposition of carcinogens through induction of cytoprotective enzymes is one of several promising strategies to prevent cancer. Chemopreventive efficacies of inducers such as dithiolethiones and sulforaphane have been extensively studied in animals as well as in humans. The KEAP1-NRF2 system is a key, but not unilateral, molecular target for these chemopreventive agents. The transcription factor NRF2 (NF-E2-related factor 2) is a master regulator of the expression of a subset of genes, which produce proteins responsible for the detoxication of electrophiles and reactive oxygen species as well as the removal or repair of some of their damage products. It is believed that chemopreventive enzyme inducers affect the interaction between KEAP1 and NRF2 through either mediating conformational changes of the KEAP1 protein or activating phosphorylation cascades targeting the KEAP1-NRF2 complex. These events in turn affect NRF2 stability and trafficking. Recent advances elucidating the underlying structural biology of KEAP1-NRF2 signaling and identification of the gene clusters under the transcriptional control of NRF2 are facilitating understanding of the potential pleiotropic effects of NRF2 activators and discovery of novel classes of potent chemopreventive agents such as the triterpenoids. Although there is appropriately a concern regarding a deleterious role of the KEAP1-NRF2 system in cancer cell biology, especially as the pathway affects cell survival and drug resistance, the development and the use of NRF2 activators as chemopreventive agents still holds a great promise for protection of normal cells from a diversity of environmental stresses that contribute to the burden of cancer and other chronic, degenerative diseases. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732782      PMCID: PMC3584341          DOI: 10.1016/j.taap.2009.08.028

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  157 in total

1.  Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.

Authors:  G S Omenn; G E Goodman; M D Thornquist; J Balmes; M R Cullen; A Glass; J P Keogh; F L Meyskens; B Valanis; J H Williams; S Barnhart; M G Cherniack; C A Brodkin; S Hammar
Journal:  J Natl Cancer Inst       Date:  1996-11-06       Impact factor: 13.506

2.  Functional antioxidant responsive elements.

Authors:  W W Wasserman; W E Fahl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene.

Authors:  R Venugopal; A K Jaiswal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins.

Authors:  K Itoh; K Igarashi; N Hayashi; M Nishizawa; M Yamamoto
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

Review 5.  Antioxidant response element.

Authors:  A K Jaiswal
Journal:  Biochem Pharmacol       Date:  1994-08-03       Impact factor: 5.858

6.  Detection of a nuclear protein which binds specifically to the antioxidant responsive element (ARE) of the human NAD(P) H:quinone oxidoreductase gene.

Authors:  B Wang; G Williamson
Journal:  Biochim Biophys Acta       Date:  1994-11-22

7.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

8.  Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz.

Authors:  C V Rao; A Rivenson; E Zang; V Steele; G Kelloff; B S Reddy
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

9.  Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters.

Authors:  M L Clapper; M Wood; K Leahy; D Lang; S Miknyoczki; B A Ruggeri
Journal:  Carcinogenesis       Date:  1995-09       Impact factor: 4.944

10.  ARE- and TRE-mediated regulation of gene expression. Response to xenobiotics and antioxidants.

Authors:  T Xie; M Belinsky; Y Xu; A K Jaiswal
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

View more
  124 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

2.  MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.

Authors:  Muhua Yang; Yuan Yao; Gabriel Eades; Yongshu Zhang; Qun Zhou
Journal:  Breast Cancer Res Treat       Date:  2011-06-03       Impact factor: 4.872

3.  Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?

Authors:  Tongde Wu; Bryan G Harder; Pak K Wong; Julie E Lang; Donna D Zhang
Journal:  Mol Carcinog       Date:  2014-08-23       Impact factor: 4.784

4.  The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.

Authors:  Irene Bobilev; Victoria Novik; Itai Levi; Ofer Shpilberg; Joseph Levy; Yoav Sharoni; George P Studzinski; Michael Danilenko
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

Review 5.  Epigenetic cancer prevention mechanisms in skin cancer.

Authors:  Kamalika Saha; Thomas J Hornyak; Richard L Eckert
Journal:  AAPS J       Date:  2013-08-01       Impact factor: 4.009

6.  Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice.

Authors:  John D Clarke; Anna Hsu; David E Williams; Roderick H Dashwood; Jan F Stevens; Masayuki Yamamoto; Emily Ho
Journal:  Pharm Res       Date:  2011-06-17       Impact factor: 4.200

7.  High-throughput screening and biosensing with fluorescent C. elegans strains.

Authors:  Chi K Leung; Andrew Deonarine; Kevin Strange; Keith P Choe
Journal:  J Vis Exp       Date:  2011-05-19       Impact factor: 1.355

Review 8.  Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer.

Authors:  Constance Lay Lay Saw; Ah-Ng Tony Kong
Journal:  Expert Opin Ther Targets       Date:  2011-01-25       Impact factor: 6.902

9.  The tobacco smoke component, acrolein, suppresses innate macrophage responses by direct alkylation of c-Jun N-terminal kinase.

Authors:  Milena Hristova; Page C Spiess; David I Kasahara; Matthew J Randall; Bin Deng; Albert van der Vliet
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01       Impact factor: 6.914

10.  Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates.

Authors:  Constance Lay-Lay Saw; Melvilí Cintrón; Tien-Yuan Wu; Yue Guo; Ying Huang; Woo-Sik Jeong; Ah-Ng Tony Kong
Journal:  Biopharm Drug Dispos       Date:  2011-06-08       Impact factor: 1.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.